Sign up Australia
Proactive Investors - Run By Investors For Investors

OBJ Limited to reveal licensing details

The halt will remain in place until Monday 24th April 2017.
OBJ Limited to reveal licensing details
The company is focused on drug delivery technology

OBJ Limited (ASX:OBJ) has been granted a trading halt by the ASX, pending details in relation to the licensing of a second technology.

The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.

View full OBJ profile

OBJ Limited Timeline

January 25 2016
December 02 2014

Related Articles

cancer cells
February 11 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use